- Home
- HE vs RAPP Comparison
HE vs RAPP Comparison
Compare HE & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HE | RAPP |
|---|---|---|
| Founded | 1891 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HE | RAPP |
|---|---|---|
| Price | $10.44 | $43.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $13.25 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 2.0M | 248.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.32 | 24.34 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $3,086,896,000.00 | N/A |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $11.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.28 | $22.75 |
| 52 Week High | $17.33 | $52.93 |
Technical Indicators
Market Signals| Indicator | HE | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 38.34 |
| Support Level | N/A | $38.95 |
| Resistance Level | $13.82 | $43.99 |
| Average True Range (ATR) | 0.27 | 2.12 |
| MACD | -0.04 | -0.98 |
| Stochastic Oscillator | 15.24 | 6.32 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.